Xtandi Clinical Trials

What are Xtandi Clinical Trials?

Xtandi is a medication that helps treat prostate cancer in men. This is usually given when cancer does not respond to hormone therapy or any surgical treatment that helps reduce testosterone in the body. It can also be given when cancer spreads throughout the body.

Xtandi has been known to slow down the rate at which prostate cancer progresses or worsens. It may also help extend life by a few months. However, it does not cure prostate cancer.

Xtandi clinical trials are needed because the medication does not do much more than extend an individual’s life. Research needs to be done to see if it can help cure prostate cancer permanently.

Why is Xtandi Being Studied through Clinical Trials?

Research shows that prostate cancer is extremely common in men. Every year, approximately 52,000 men are reported to develop prostate cancer. This amounts to 142 men every single day. One man loses his life due to prostate cancer every 45 minutes. Moreover, 1 in every 8 men gets diagnosed with prostate cancer.

These statistics show that Xtandi clinical trials are extremely important. More research needs to be done on treatments for prostate cancer and whether Xtandi can be worked on and developed so that it becomes a medication to reduce the intensity of cancer and, over time, aid in its cure.

What are the Types of Treatments Available for Prostate Cancer?

• Surgery: An operation known as prostatectomy is performed on individuals with prostate cancer. It involves removing the prostate completely.
• Radiation therapy: This is similar to x-rays which are used to kill cancer completely. There are two kinds of radiation therapy, including external radiation therapy and internal radiation therapy.
• Cryotherapy: This involves putting a probe near the cancer, which helps freeze and eventually kills the cancer-causing cells in the body.
• High-intensity focused ultrasound: This involves high-intensity sound waves that are used to kill cancer cells.

What are Some Recent Breakthrough Clinical Trials for Xtandi?

2023: Safety and Efficacy Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)- This clinical trial focused on assessing the safety of enzalutamide in individuals who have non-metastatic prostate cancer. The experimental group was given 160 mg of the medication orally every single day, while the other group was given a placebo,

It was found that those who were given Xtandi showed a slower progression of the disease. Other treatment plans were used in addition to Xtandi, and it was found that these individuals were able to recover from some part of prostate cancer as compared to those taking a placebo and going through alternate treatments.

2019: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer- This Xtandi clinical trial aimed to study whether enzalutamide, coupled with testosterone suppression, helped increase survival rates in patients with hormone-sensitive, metastatic prostate cancer.

Out of the 1125 participants, those who were given enzalutamide experienced more fatigue and seizures. However, they also experienced longer progression-free and higher survival rates than other men in the group.